1032823-75-8

Storage:at -20℃ 2 years

Biologieal

GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. In the intravenous glucose tolerance test, significant increases in the peak insulin response and insulin AUC(0-15 min) of 30-60% were reported in the GSK1292263 treatment group, compared with values in the vehicle control cohort. This insulin upregulation correlated with a significant increase in the glucose disposal rate.

Reference

[1] http://professional.diabetes.org/News_Display.aspx?CID=82333&TYP=9